TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: In a phase 3, randomized trial (ECHELON-2, NCT01777152), BV combined with CHP achieved superior PFS and OS rates compared with CHOP in patients with newly diagnosed CD30-expressing PTCL.